Letrozole

Drug Profile

Letrozole

Alternative Names: CGP 20267; CGS 20267; Femara

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Developer M. D. Anderson Cancer Center; National Cancer Institute (USA); Novartis
  • Class Antineoplastics; Nitriles; Small molecules; Triazoles
  • Mechanism of Action Aromatase inhibitors; Estrogen receptor antagonists; Estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Endometrial cancer; Fallopian tube cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cancer
  • Discontinued Delayed puberty; Endometriosis; Female infertility

Most Recent Events

  • 01 Jul 2017 Novartis and M.D. Anderson Cancer Center terminates a phase II trial in Leiomyosarcoma (Newly diagnosed, Adjuvant therapy) in USA due to low accrual (NCT00414076)
  • 09 May 2017 The US FDA approves ribociclib tablets and letrozole tablets combination pack for treatment of HR+/HER2- advanced or metastatic breast cancer in USA
  • 21 Feb 2017 University of Colorado plans a phase I/II trial for Breast cancer (Combination therapy, Metastatic disease, Inoperable/Unresectable) in USA (NCT03054363)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top